Sachin R Jhawar

Dr. Sachin R Jhawar

The Ohio State University Wexner Medical Center, Columbus, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Seminars in Nephrology
Verified
Journal Article
Closed access
RMRosalinde Masereeuw
Rosalinde Masereeuw
HMHenricus Mutsaers
Henricus Mutsaers
TTTakafumi Toyohara
Takafumi Toyohara
TATakaaki Abe
Takaaki Abe
SJSachin R Jhawar
Sachin R Jhawar
Jerome LowensteinJerome Lowenstein
Jerome Lowenstein

31 March 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
LNLama Nazzal
Lama Nazzal
JRJulia Roberts
Julia Roberts
PSPrabhjot Singh
Prabhjot Singh
SJSachin R Jhawar
Sachin R Jhawar
AMAlbert Matalon
Albert Matalon
Jerome LowensteinJerome Lowenstein
Jerome Lowenstein
Observational studies have suggested a relationship between the plasma concentration of indoxyl sulfate (IS) and p-cresyl sulfate (PCS), small gut-derived ‘uremic solutes’, and the high incidence of uremic cardiomyopathy in patients with end-stage renal disease (ESRD). IS and PCS are derived from the metabolism of dietary components (tryptophan and tyrosine) by gut bacteria. This pilot study was designed to examine the effects of a poorly absorbable antibiotic (vancomycin) on the plasma concentration of two gut-derived ‘uremic solutes’, IS and PCS, and on the composition of the gut microbiome. Plasma concentrations of IS and PCS were measured by MS-HPLC. The gut microbiome was assessed in stool specimens sequenced for the 16S rRNA gene targeting the V4 region. The pre-dialysis mean plasma concentrations of both IS and PCS were markedly elevated. Following the administration of vancomycin (Day 0), the IS and PCS concentrations decreased at Day 2 or Day 5 and returned to baseline by Day 28. Following vancomycin administration, several changes in the gut microbiome were observed. Most striking was the decrease in diversity, a finding that was evident on Day 7 and was still evident at Day 28. There was little change at the phylum level but at the genus level, broad population changes were noted. Changes in the abundance of several genera appeared to parallel the concentration of IS and PCS. These findings suggest that alteration of the gut microbiome, by an antibiotic, might provide an important strategy in reducing the levels of IS and PCS in ESRD.

1 February 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
AYAlexander Yaney
Alexander Yaney
AAAhmet S. Ayan
Ahmet S. Ayan
XPXueliang Pan
Xueliang Pan
SJSachin R Jhawar
Sachin R Jhawar
EHErin Healy
Erin Healy
JBJose G Bazan
Jose G Bazan

15 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SBSujith Baliga
Sujith Baliga
VYVedat O. Yildiz
Vedat O. Yildiz
JBJose G. Bazan
Jose G. Bazan
Joshua PalmerJoshua Palmer
Joshua Palmer
SJSachin R Jhawar
Sachin R Jhawar
MGMauricio Gamez
Mauricio Gamez
Background: Racial/ethnic (R/E) minorities with head and neck squamous cell carcinoma (HNSCC) have worse survival outcomes compared to White patients. While disparities in patient outcomes for R/E minorities have been well documented, the specific drivers of the inferior outcomes remain poorly understood. Patients and Methods: This was a population-based retrospective cohort study that analyzed HNSCC patients using the National Cancer Database (NCDB) from 2000–2016. Patient outcomes were stratified by R/E groups including White, Black, Hispanic, Native American/Other, and Asian. The main outcome in this study was overall survival (OS). Univariate time-to-event survival analyses were performed using the Kaplan–Meier product limit estimates and the log-rank test to evaluate the differences between strata. Results: There were 304,138 patients with HNSCC identified in this study, of which 262,762 (86.3%) were White, 32,528 (10.6%) were Black, 6191 were Asian (2.0%), and 2657 were Native American/Other (0.9%). Black R/E minorities were more likely to be uninsured (9% vs. 5%, p < 0.0001), have Medicaid insurance (22% vs. 8%, p < 0.0001), be in a lower income quartile (<30,000, 42% vs. 13%, p < 0.0001), have metastatic disease (5% vs. 2%, p < 0.001), and have a total treatment time 6 days longer than White patients (median 107 vs. 101 days, p < 0.001). The 5-year OS for White, Black, Native American/Other, and Asian patients was 50.8%, 38.6%, 51.1%, and 55.8%, respectively. Among the oropharynx HNSCC patients, the 5-year OS rates in p16+ White, Black, and Asian patients were 65.7%, 39.4%%, and 55%, respectively. After a multivariate analysis, Black race was still associated with an inferior OS (HR:1.09, 95% CI: 1.03–1.15, p = 0.002). Conclusions: This large cohort study of HNSCC patients demonstrates that Black race is independently associated with worse OS, in part due to socioeconomic, clinical, and treatment-related factors.

10 December 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AEArielle Elkrief
Arielle Elkrief
JWJulie Wu
Julie Wu
CJChinmay T. Jani
Chinmay T. Jani
KEKyle T. Enriquez
Kyle T. Enriquez
MGMichael Glover
Michael Glover
JWJeremy L. Warner
Jeremy L. Warner
The ongoing coronavirus disease 2019 (COVID-19) pandemic has left patients with current or past history of cancer facing disparate consequences at every stage of the cancer trajectory. This comprehensive review offers a landscape analysis of the current state of the literature on COVID-19 and cancer, including the immune response to COVID-19, risk factors for severe disease, and impact of anticancer therapies. We also review the latest data on treatment of COVID-19 and vaccination safety and efficacy in patients with cancer, as well as the impact of the pandemic on cancer care, including the urgent need for rapid evidence generation and real-world study designs.Significance:. Patients with cancer have faced severe consequences at every stage of the cancer journey due to the COVID-19 pandemic. This comprehensive review offers a landscape analysis of the current state of the field regarding COVID-19 and cancer. We cover the immune response, risk factors for severe disease, and implications for vaccination in patients with cancer, as well as the impact of the COVID-19 pandemic on cancer care delivery. Overall, this review provides an in-depth summary of the key issues facing patients with cancer during this unprecedented health crisis.

1 August 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SJSachin R Jhawar
Sachin R Jhawar
LHLara Hathout
Lara Hathout
MEMohamed A. Elshaikh
Mohamed A. Elshaikh
SBSushil Beriwal
Sushil Beriwal
WSWilliam Small
William Small
OMOmar Mahmoud
Omar Mahmoud